A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
Sponsored by Hoffmann-La Roche
About this study
This Phase III, multicenter, double-blind, placebo-controlled treat-through study will evaluate the efficacy and safety of induction and maintenance therapy with Afimkibart (also known as RO7790121) in participants with moderately to severely active Crohn's disease (CD).
Where this study is enrolling (6)
- Call +1 480-342-2000
Mayo Clinic Hospital
Phoenix, Arizona
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
- I'm interested
University of Arizona-CATS Research Center
Tucson, Arizona
- I'm interested
Digestive Healthcare of Georgia
Atlanta, Georgia
- I'm interested
Atlanta Gastroenterology Associates
Atlanta, Georgia
- Call 312.926.2000
Northwestern Memorial Hospital
Chicago, Illinois
This research site can be reached directly by phone. Call to ask about this study.
Create a free account to get updates on similar Clinical Trials for your conditions.
Show all 6 locations
- I'm interested
Baylor College of Medicine
Houston, Texas
Who can participate
Inclusion criteria
- ✓Confirmed diagnosis of CD
- ✓Moderately to severely active CD
- ✓Bodyweight \>= 40 kilogram (kg)
- ✓Demonstrated inadequate response, loss of response and/or intolerance to at least one protocol-specified conventional or advanced CD therapy
- ✓Males and females of childbearing potential must meet protocol criteria for contraception requirements
Exclusion criteria
- ✕Current diagnosis of ulcerative colitis (UC) or indeterminate colitis, ischemic colitis, infectious colitis, radiation colitis, microscopic colitis
- ✕Participant with a history of \>= 3 bowel resections (\> 2 missing segments of the 5 following segments: terminal ilelium, right colon, transverse colon, sigmoid and left colon, and rectum)
- ✕Diagnosis of short gut or short bowel syndrome
- ✕Presence of an ileostomy, colostomy or ileoanal pouch
- ✕Participants with symptomatic bowel strictures, fulminant colitis, or toxic megacolon
- ✕Presence of abdominal or perianal abscess
- ✕Presence of rectovaginal, enterovaginal, high output enterocutaneous fistula, enterovesical fistulas or perianal fistulas with \>3 openings
- ✕Current diagnosis or suspicion of primary sclerosing cholangitis
- ✕Pregnancy or breastfeeding, or intention of becoming pregnant during the study
- ✕Any past or current evidence of cancer of gastrointestinal tract, definite low-grade or high-grade colonic dysplasia
- ✕History of non-gastrointestinal cancer, with the exception of adequately treated non-metastatic basal cell or squamous cell skin cancer or in situ cervical cancer
- ✕Evidence of infection with Clostridioides difficile (C. difficile; formerly known as Clostridium difficile), cytomegalovirus (CMV), human immunodeficiency virus (HIV), Hepatitis B (HBV), Hepatitis C (HCV) during screening
- ✕Has evidence of active tuberculosis (TB), latent TB not successfully treated (per local guidance) or inadequately treated TB
- ✕Has received protocol-specified prohibited medicines, including known exposure to any type of anti-TL1A therapy
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.